Rivière, Elodie
Sellam, Jérémie
Pascaud, Juliette
Ravaud, Philippe
Gottenberg, Jacques-Eric
Mariette, Xavier
Funding for this research was provided by:
French Ministery of Health (2009-013482-26)
Direction de la recherche clinique et de l'Innovation
Article History
First Online: 8 June 2018
Ethics approval and consent to participate
: The trial (Clinicaltrials.gov identifier NCT01000441) was approved by the institutional review board of the Comité de Protection des Personnes-Est 1, Strasbourg, France. The study was conducted according to the current regulations of the International Conference on Harmonization guidelines and the principles of the Declaration of Helsinki. All patients gave written informed consent after receiving oral and written information about the trial.
: We confirm that all authors approved the manuscript for submission.
: Dr. Rivière reported receiving a PhD grant from Fondation Arhtirits Courtin.Dr. Sellam reported receiving grant support from Roche, Bristol-Myers Squibb, and Pfizer and personal fees from Roche, Pfizer, Abbvie, Bristol-Myers Squibb, Merck Sharp and Dohme, UCB, Janssen, Sandoz, and Novartis.Dr. Gottenberg reported receiving grant support from Abbvie, Pfizer, and Roche and personal fees from Bristol-Myers Squibb, Merck, Sharp, and Dohme, UCB, GlaxoSmithKline, and Novartis.Dr. Mariette reported receiving personal fees from Pfizer, UCB, Bristol-Myers Squibb, and GlaxoSmithKline and grant support from Roche, Pfizer, Bristol-Myers Squibb, GlaxoSmithKline, and Biogen.No other disclosures were reported.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.